Targeted radiotherapy powered by Biotech

Radiopharmaceuticals have turned into a hot commodity when it comes to M&A financing and deals. Targeted therapies that employ high-energy attachments linked to antibodies, small molecules or peptides promise fewer side effects and a localised attack on the tumour. Novartis initially cracked open the door with an innovation from France. Now investors are trying to play catch-up, and startups have seen a surge in demand. The companies involved are both toolmakers and those digging for radioactive gold.